{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T23:35:42Z","timestamp":1772580942421,"version":"3.50.1"},"reference-count":17,"publisher":"The Endocrine Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Context: Excess GH and IGF-I in acromegaly are associated with reduced life expectancy due to cardiovascular complications.<\/jats:p>\n               <jats:p>Objective: The objective of the study was to investigate the prevalence, incidence, and severity of cardiac valve regurgitation before and after somatostatin-analog treatment in acromegaly.<\/jats:p>\n               <jats:p>Design: This was a prospective, observer-blinded, multicenter, 12-month study.<\/jats:p>\n               <jats:p>Setting: The study was conducted at 33 specialist centers.<\/jats:p>\n               <jats:p>Patients: The study population consisted of 225 adult patients with acromegaly without significant cardiac valve abnormalities or prior valve-replacement surgery, matched for age, sex, and center\/country\/study.<\/jats:p>\n               <jats:p>Interventions: Interventions included initiation\/continuation of lanreotide (n = 107) or octreotide treatment (n = 118), tailored for optimal disease control.<\/jats:p>\n               <jats:p>Main Outcome Measures: Relative risk of new\/worsening regurgitation in any valve at 12 months compared with baseline, was measured.<\/jats:p>\n               <jats:p>Results: At baseline, almost 80% of patients had some degree of cardiac valve regurgitation, although none was severe. The risk of developing new\/worsening regurgitation in any valve at 12 months was nonsignificant and similar for the cohorts [adjusted odds ratio 0.86; 95% confidence interval (CI) 0.41\u20131.82; P = 0.694; relative risk 1.04; 95% CI 0.67\u20131.60; risk difference 0.01; 95% CI \u22120.13 to 0.16]. For 54% of patients, the severity of regurgitation stayed the same during the study. At baseline, significant valve regurgitation occurred in 18% of patients (lanreotide cohort) and 13% (octreotide cohort) and at 12 months in 18% of each cohort.<\/jats:p>\n               <jats:p>Conclusions: The incidence of valve regurgitation did not change over 12 months of treatment with somatostatin analogs, and most cases were physiologic or mild in severity. There was no significant difference between somatostatin analogs in the risk of developing new\/worsening valve regurgitation or significant regurgitation after 1 yr.<\/jats:p>","DOI":"10.1210\/jc.2007-2199","type":"journal-article","created":{"date-parts":[[2008,4,2]],"date-time":"2008-04-02T03:08:57Z","timestamp":1207105737000},"page":"2243-2248","source":"Crossref","is-referenced-by-count":27,"title":["No Greater Incidence or Worsening of Cardiac Valve Regurgitation with Somatostatin Analog Treatment of Acromegaly"],"prefix":"10.1210","volume":"93","author":[{"given":"Annamaria","family":"Colao","sequence":"first","affiliation":[{"name":"Department of Molecular and Clinical Endocrinology and Oncology (A.C.), Charles University, Prague 12108, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef","family":"Marek","sequence":"additional","affiliation":[{"name":"Department of Federico II University of Naples, 80131 Naples, Italy; 1st School of Medicine (J.M.), Charles University, Prague 12108, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miklos I.","family":"Goth","sequence":"additional","affiliation":[{"name":"Division of Endocrinology (M.I.G.), Department of Medicine, National Medical Center, Budapest 1135, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Caron","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolic Diseases (P.C.), Centre Hospitalier Universitaire Larrey, Toulouse 31059, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Marc","family":"Kuhn","sequence":"additional","affiliation":[{"name":"Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale 0204 (J.M.K.), Ho\u0302pital Centre d\u2019Investigation Clinique, Charles Nicolle, Rouen 76031, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco M.","family":"Minuto","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism (F.M.M.), University of Genova, 16132 Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil J.","family":"Weissman","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Research Institute\/Washington Hospital Center (N.J.W.), Washington, DC 20010"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"2020071613252181900_R1","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1210\/er.2002-0022","article-title":"Systemic complications of acromegaly: epidemiology, pathogenesis, and management.","volume":"25","author":"Colao","year":"2004","journal-title":"Endocr Rev"},{"key":"2020071613252181900_R2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0002-8703(80)90277-X","article-title":"Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients.","volume":"100","author":"Lie","year":"1980","journal-title":"Am Heart J"},{"key":"2020071613252181900_R3","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1210\/jc.2002-021099","article-title":"High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study.","volume":"88","author":"Colao","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613252181900_R4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1210\/jc.2003-030849","article-title":"Increased prevalence of regurgitant valvular heart disease in acromegaly.","volume":"89","author":"Pereira","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613252181900_R5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ghir.2006.02.002","article-title":"Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation.","volume":"16","author":"van der Klaauw","year":"2006","journal-title":"Growth Horm IGF Res"},{"key":"2020071613252181900_R6","first-page":"1086","article-title":"American Society of Echocardiography recommendations for use of echocardiography in clinical trials.","volume":"17","author":"Gottdiener","year":"2004","journal-title":"J Am Soc Echocardiogr"},{"key":"2020071613252181900_R7","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0894-7317(03)00335-3","article-title":"Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography.","volume":"16","author":"Zoghbi","year":"2003","journal-title":"J Am Soc Echocardiogr"},{"key":"2020071613252181900_R8","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/S0735-1097(87)80254-1","article-title":"Evaluation of aortic insufficiency by Doppler color flow mapping.","volume":"9","author":"Perry","year":"1987","journal-title":"J Am Coll Cardiol"},{"key":"2020071613252181900_R9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1161\/01.CIR.75.1.175","article-title":"Color Doppler assessment of mitral regurgitation with orthogonal planes.","volume":"75","author":"Helmcke","year":"1987","journal-title":"Circulation"},{"key":"2020071613252181900_R10","first-page":"1","article-title":"Mortality in acromegaly.","volume":"39","author":"Wright","year":"1970","journal-title":"Q J Med"},{"key":"2020071613252181900_R11","first-page":"2730","article-title":"Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group.","volume":"83","author":"Orme","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613252181900_R12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2265.1994.tb03789.x","article-title":"Determinants of clinical outcome and survival in acromegaly.","volume":"41","author":"Rajasoorya","year":"1994","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071613252181900_R13","first-page":"293","article-title":"An audit of outcome of treatment in acromegaly.","volume":"86","author":"Bates","year":"1993","journal-title":"Q J Med"},{"key":"2020071613252181900_R14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1210\/jcem.87.1.8153","article-title":"Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.","volume":"87","author":"Caron","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613252181900_R15","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1530\/eje.0.1500473","article-title":"The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR.","volume":"150","author":"Ashwell","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"2020071613252181900_R16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1046\/j.1365-2265.1998.00389.x","article-title":"Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly.","volume":"48","author":"Davies","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071613252181900_R17","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1210\/jcem.87.7.8665","article-title":"Somatostatin analogs in acromegaly.","volume":"87","author":"Freda","year":"2002","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/93\/6\/2243\/9057071\/jcem2243.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/93\/6\/2243\/9057071\/jcem2243.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T23:46:24Z","timestamp":1594943184000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/93\/6\/2243\/2598730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,1]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2007-2199","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6,1]]}}}